0000000000612987

AUTHOR

R. Porcasi

showing 4 related works from this author

Value of bone marrow biopsy in the diagnosis of essential thrombocythemia.

2004

Background and Objectives. Essential thrombocythemia (ET) is a Philadelphia chromosome-negative chronic myeloproliferative disorder (CMPD) whose diagnosis, according to the Polycythemia Vera Study Group (PVSG) criteria, does not include histopathological data. The new WHO classification of CMPD has supplied new diagnostic guidelines which highlight the value of histopathology and facilitate a more precise differentiation of ET from reactive conditions and other CMPD. Design and Methods. Bone marrow biopsies from 142 adult patients diagnosed with ET according to PVSG criteria were evaluated using the new WHO classification. Megakaryocyte morphology and arrangement, amount of fibrosis and a c…

AdultAged 80 and overAge DistributionAntigens CDBone MarrowBiopsyHumansReproducibility of ResultsAntigens CD34Mast Cell microenvironment angioimmunoblasticMiddle AgedAgedThrombocythemia Essential
researchProduct

Pleomorphic adenoma of the lateral nasal wall: case report.

2008

Pleomorphic adenoma is the most common tumour of the salivary glands. However, it is extremely rare for these to originate in the nose and even when they do so, it is most commonly in the nasal septum. It is important to be aware of the paucity of presenting symptoms (nasal obstruction and epistaxis), as the lesion may not be recognized immediately. Growth is generally restricted locally and the tumour is not known to spread to the neighbouring structures. Surgical resection is the treatment of choice. Recurrences and evolution to malignancy are not frequent, but long-term follow-up is recommended. The case is presented of pleomorphic adenoma arising from the lateral wall of the right nasal…

AdultMaleOlfaction DisordersCase reportNose NeoplasmsAdenoma PleomorphicNose • Nasal tumour • Pleomorphic adenoma • Diagnosis • HistopathologyHumansNasal Obstruction
researchProduct

Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis

2009

Objective Subclinical gut inflammation is common in spondylarthritis, but the immunologic abnormalities underlying this process are undefined. Perturbation of the interleukin-23 (IL-23)/Th17 axis has emerged as a fundamental trigger of chronic inflammation. This study was undertaken to investigate the expression and tissue distribution of IL-23/Th17–related molecules in Crohn's disease (CD) and in subclinical gut inflammation in ankylosing spondylitis (AS). Methods Quantitative gene expression analysis of Th1/Th2 and IL-23/Th17 responses was performed in intestinal biopsy samples obtained from 12 patients with CD, 15 patients with AS, and 13 controls. IL-23 tissue distribution and identific…

AdultMalePaneth Cellschronic inflammationPathologymedicine.medical_specialtyImmunologyGene ExpressionInflammationMonocytesTh2 CellsRheumatologyIntestinal mucosaIleumankylosing spondylitisPrevalencemedicineInterleukin 23HumansImmunology and Allergyinterleukin-23 (IL-23); Th 17;chronic inflammation; Crohn's disease; ankylosing spondylitisSpondylitis AnkylosingPharmacology (medical)IleitisRNA MessengerIntestinal MucosaSpondylitisinterleukin-23 (IL-23)Subclinical infectionAnkylosing spondylitisbusiness.industryInterleukin-17IleitisMiddle AgedTh1 Cellsmedicine.diseaseUp-RegulationCrohn's diseaseSTAT1 Transcription FactorTh 17ImmunologyInterleukin-23 Subunit p19FemaleInterleukin 17medicine.symptombusinessArthritis & Rheumatism
researchProduct

P-selectin glycoprotein ligand-1 as a potential target for humoral immunotherapy of multiple myeloma.

2008

Monoclonal antibodies (mAbs), successfully adopted in the treatment of several haematological malignancies, have proved almost ineffective in multiple myeloma (MM), because of the lack of an appropriate antigen for targeting and killing MM cells. Here, we demonstrate that PSGL1, the major ligand of P-Selectin, a marker of plasmacytic differentiation expressed at high levels on normal and neoplastic plasma cells, may represent a novel target for mAb-mediated MM immunotherapy. The primary effectors of mAb-induced cell-death, complement-mediated lysis (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), were investigated using U266B1 and LP1 cell-lines as models. Along with immunolo…

Cytotoxicity ImmunologicMembrane Glycoproteinsmieloma multiplo; ab therapy; PSGL-1ab therapyAntibody-Dependent Cell CytotoxicityDrug Evaluation PreclinicalAntibodies MonoclonalBone Marrow CellsSettore MED/08 - Anatomia Patologicamultiple myelomaDrug Delivery SystemsCell Line TumorHumanscomplementimmunotherapymieloma multiploPSGL-1ADCCComplement Activationmonoclonal antibodie
researchProduct